Cowen analyst Ritu Baral reiterated an Outperform rating on Krystal Biotech (NASDAQ: KRYS) and highlighted the company as an under-the-radar ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE